Atrial Fibrillation
Conditions
Keywords
cardio-oncology, cardiotoxicity, hematologic malignancy, atrial fibrillation, rhythm disorders, insertable subcutaneous cardiac monitor
Brief summary
The goal of this clinical trial is to screen all types of electrocardiographic changes and rhythm disorders in adult patients with a hematologic malignancy requiring a treatment by Bruton's tyrosine kinase (BTK) inhibitor (ibrutinib, acalabrutinib, zanubrutinib) using an insertable subcutaneous cardiac monitor (ISCM) and occurring from inclusion and within 12 months. This study consists of the implantation of an ISCM at inclusion and before BTK inhibitor initiation. Then patients will have medical visits every 3 months (+/- 7 days) during 12 months and a continuous cardiac telemonitoring using the ISCM.
Interventions
DEVICEInsertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)
Implantation of a subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®) before beginning the Bruton's tyrosine kinase inhibitor treatment.
Sponsors
University Hospital, Marseille
Groupe Hospitalier Pitie-Salpetriere
European Georges Pompidou Hospital
Hôpital Necker-Enfants Malades
Saint Antoine University Hospital
Hospices Civils de Lyon
Centre Hospitalier Universitaire de Saint Etienne
Biotronik SE & Co. KG
University Hospital, Caen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients, * Definite diagnosis of hematologic malignancy requiring a BTK inhibition with ibrutinib, acalabrutinib or zanubrutinib, * Expected BTK inhibitor duration estimated to be at least 12 months, * Sinus rhythm at enrolment, * Willing to sign patient consent form and to comply with scheduled visits, as outlined in the protocol
Exclusion criteria
* Age \< 18 years old, * Adults with protective measures (curatorship or tutorship) and vulnerable patients, * Pregnant or nursing women, * Permanent atrial fibrillation or long-standing persistent atrial fibrillation as defined by the European Society of Cardiology guidelines, * Atrial fibrillation on the electrocardiogram at the inclusion visit, * Previous left atrial ablation or previous maze or maze-like surgery, * Indication for or patients with a pacemaker or implantable cardioverter-defibrillator at baseline, * Untreated hyperthyroidism, * Uncorrected kaliaemia disorders at the inclusion visit, * Hemoglobin \< 8 g/L at the inclusion visit, * Thrombopenia \< 50,000/mm3 at the inclusion visit, * Active bleeding, * Myocardial infarction \< 1 month, * Surgery \< 1 month, * Mechanical heart valve, * Valvular heart disease requiring surgery, * Inability to follow the required procedures of the clinical investigation plan, * No signature of patient consent form.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of any electrocardiographic changes and/or rhythm disorders from first BTK inhibitors prescription to 12 months of follow-up, symptomatic or not, detected on 12-lead ECG and/or on ISCM. | 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days) | Electrocardiographic changes and/or rhythm disorders are defined by the European Society of Cardiology guidelines. |
Secondary
| Measure | Time frame |
|---|---|
| The occurrence of bleeding events from inclusion and within 12 months. | 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days) |
| Correlation between IRAF and multiple demographic, clinical, cardiac imaging (morphological data) and serum cardiac biomarkers. | 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days) |
| IRAF management. | 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days) |
| Progression-free survival of patients treated by BTK inhibitors according to the presence of IRAF. | 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days) |
| Electrocardiographic intervals (PR, QRS, QT) measurements on both 12-lead ECG and ISCM at baseline and with BTK inhibitors exposure. | 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days) |
| Daily body temperature monitoring with the ISCM (BIOMONITOR IIIm®, Biotronik®) temperature sensor and will be compared with conventional body temperature measurements performed during follow-up visits. | 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days) |
| Constitute a plasmatic biobank for futures ancillary studies. | 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days) |
| The need for ISCM (BIOMONITOR IIIm®, Biotronik®) remove within the 12-months follow-up. | 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days) |
| Correlation between QT/QTc measurements performed by ISCM (BIOMONITOR IIIm®, Biotronik®) and a QT expert on 12-leads ECG. | 3, 6, 9 and 12 months after introduction of ibrutinib therapy (+/- 7 days) |
Countries
France
Contacts
Primary ContactJoachim Alexandre, MD, PhD
Outcome results
None listed